Suzanne L Elliott

Suzanne L Elliott

UNVERIFIED PROFILE

Are you Suzanne L Elliott?   Register this Author

Register author
Suzanne L Elliott

Suzanne L Elliott

Publications by authors named "Suzanne L Elliott"

Are you Suzanne L Elliott?   Register this Author

9Publications

102Reads

39Profile Views

Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials.

BMJ Open 2019 01 15;9(1):e024224. Epub 2019 Jan 15.

School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2018-024224DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340482PMC
January 2019

Fasting increases serum bilirubin levels in clinically normal, healthy males but not females: a retrospective study from phase I clinical trial participants.

J Clin Pathol 2014 Jun 4;67(6):529-34. Epub 2014 Mar 4.

Faculty of Health, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.

View Article

Download full-text PDF

Source
http://jcp.bmj.com/lookup/doi/10.1136/jclinpath-2013-202155
Publisher Site
http://dx.doi.org/10.1136/jclinpath-2013-202155DOI Listing
June 2014

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.

Vaccine 2010 Mar 4;28(10):2236-2242. Epub 2010 Jan 4.

Malaria Vaccine Development Branch (MVDB), National Institute of Allergy and Infectious Disease, National Institutes of Health (NIAID/NIH), Rockville, MD, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2009.12.049DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847846PMC
March 2010

Determining virological, serological and immunological parameters of EBV infection in the development of PTLD.

Int Immunol 2004 Jul 24;16(7):983-9. Epub 2004 May 24.

Division of Immunology and Infectious Diseases and the Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research and University of Queensland Joint Oncology Program, Brisbane, 4029 Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/intimm/dxh099DOI Listing
July 2004

Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.

Cancer Immunol Immunother 2003 Jun 8;52(6):387-95. Epub 2003 Apr 8.

Melanoma Therapy Group, Mater Misericordiae Adult Hospital, Raymond Terrace, 4101, South Brisbane, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-003-0375-xDOI Listing
June 2003

Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.

Transplantation 2003 May;75(9):1556-60

The Cooperative Research Centre for Vaccine Technology, Division of Immunology and Infectious Diseases, The Queensland Institute of Medical Research and University of Queensland Joint Oncology Program, Brisbane, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.TP.0000058745.02123.6FDOI Listing
May 2003

Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias.

J Immunol 2003 Mar;170(5):2599-604

Queensland Institute of Medical Research, Cooperative Research Center for Vaccine Technology, Australian Center for International & Tropical Health & Nutrition, Brisbane, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.170.5.2599DOI Listing
March 2003